6-(2,4-difluorophenoxy)-2-isopropylamino-8-methyl-8H-pyrido[2,3-d]pyrimidin-7-one | 852022-92-5

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 6-(2,4-difluorophenoxy)-2-isopropylamino-8-methyl-8H-pyrido[2,3-d]pyrimidin-7-one
• 英文别名: 6-(2,4-difluorophenoxy)-8-methyl-2-[(1-methylethyl)amino]pyrido[2,3-d]pyrimidin-7(8H)-one；6-(2,4-difluorophenoxy)-8-methyl-2-(propan-2-ylamino)pyrido[2,3-d]pyrimidin-7-one
• CAS: 852022-92-5
• 化学式: C₁₇H₁₆F₂N₄O₂
• 分子量: 346.336
• InChiKey: HAVJVJFXQRMACG-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.2
• 重原子数：
  25
• 可旋转键数：
  4
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.24
• 拓扑面积：
  67.4
• 氢给体数：
  1
• 氢受体数：
  7

反应信息

• 作为反应物：
  描述：

  6-(2,4-difluorophenoxy)-2-isopropylamino-8-methyl-8H-pyrido[2,3-d]pyrimidin-7-one 在 盐酸 作用下， 以 甲醇 、 乙醚 为溶剂， 反应 0.5h， 以0.317 g的产率得到6-(2,4-difluorophenoxy)-2-isopropylamino-8-methyl-8H-pyrido[2,3-d]pyrimidin-7-one hydrochloride.
  参考文献：
  名称：

  Discovery of 6-(2,4-Difluorophenoxy)-2-[3-hydroxy-1-(2-hydroxyethyl)propylamino]-8-methyl-8H-pyrido[2,3-d]pyrimidin-7-one (Pamapimod) and 6-(2,4-Difluorophenoxy)-8-methyl-2-(tetrahydro-2H-pyran-4-ylamino)pyrido[2,3-d]pyrimidin-7(8H)-one (R1487) as Orally Bioavailable and Highly Selective Inhibitors of p38α Mitogen-Activated Protein Kinase

  摘要：

  The development of a new series of p38 alpha inhibitors resulted in the identification of two clinical candidates, one of which was advanced into a phase 2 clinical study for rheumatoid arthritis. The original lead, an lck inhibitor that also potently inhibited p38a, was a screening hit from our kinase inhibitor library. This manuscript describes the optimization of the lead to p38-selective examples with good pharmacokinetic properties.

  DOI：

  10.1021/jm101423y
• 作为产物：
  描述：

  4-甲胺基-2-甲硫基-5-嘧啶甲酸乙酯 在 manganese(IV) oxide 、 lithium aluminium tetrahydride 、 甲酸 、 双氧水 、 potassium carbonate 作用下， 以 四氢呋喃 、 N-甲基吡咯烷酮 、 二氯甲烷 、 水 为溶剂， 反应 43.25h， 生成 6-(2,4-difluorophenoxy)-2-isopropylamino-8-methyl-8H-pyrido[2,3-d]pyrimidin-7-one
  参考文献：
  名称：

  Discovery of 6-(2,4-Difluorophenoxy)-2-[3-hydroxy-1-(2-hydroxyethyl)propylamino]-8-methyl-8H-pyrido[2,3-d]pyrimidin-7-one (Pamapimod) and 6-(2,4-Difluorophenoxy)-8-methyl-2-(tetrahydro-2H-pyran-4-ylamino)pyrido[2,3-d]pyrimidin-7(8H)-one (R1487) as Orally Bioavailable and Highly Selective Inhibitors of p38α Mitogen-Activated Protein Kinase

  摘要：

  The development of a new series of p38 alpha inhibitors resulted in the identification of two clinical candidates, one of which was advanced into a phase 2 clinical study for rheumatoid arthritis. The original lead, an lck inhibitor that also potently inhibited p38a, was a screening hit from our kinase inhibitor library. This manuscript describes the optimization of the lead to p38-selective examples with good pharmacokinetic properties.

  DOI：

  10.1021/jm101423y

文献信息

• Hydroxyalkyl substituted pyrido-7-pyrimidin-7-ones
  申请人：Goldstein Michael David

  公开号：US20080119497A1

  公开（公告）日：2008-05-22

  Compounds of the Formula: where X 1 , Ar 1 , R 1 , and R 2 are as defined herein, and compositions comprising the same. Also provided are methods for using compounds of Formula I in treating p38 mediated disorders in a patient.

  本发明提供了以下公式的化合物：其中X1，Ar1，R1和R2如定义所述，并且包括这些化合物的组合物。还提供了使用公式I的化合物治疗患者的p38介导的疾病的方法。
• US7348331B2
  申请人：——

  公开号：US7348331B2

  公开（公告）日：2008-03-25
• US7750016B2
  申请人：——

  公开号：US7750016B2

  公开（公告）日：2010-07-06